Dyne Therapeutics’ (DYN) “Buy” Rating Reaffirmed at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research note released on Monday morning,Benzinga reports. Chardan Capital currently has a $38.00 target price on the stock.

DYN has been the topic of several other reports. Wall Street Zen lowered shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, December 28th. Oppenheimer raised shares of Dyne Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $11.00 to $40.00 in a research report on Wednesday, December 10th. Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday. Stifel Nicolaus upped their target price on shares of Dyne Therapeutics from $36.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Finally, Evercore cut their target price on shares of Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Monday, December 15th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $36.13.

Dyne Therapeutics Stock Up 19.0%

NASDAQ:DYN opened at $17.69 on Monday. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $25.00. The firm has a market capitalization of $2.92 billion, a price-to-earnings ratio of -5.00 and a beta of 1.34. The company has a quick ratio of 22.25, a current ratio of 22.25 and a debt-to-equity ratio of 0.15. The stock’s 50 day moving average price is $17.01 and its two-hundred day moving average price is $17.15.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.02). Equities research analysts expect that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Aberdeen Group plc boosted its holdings in shares of Dyne Therapeutics by 15.0% during the 3rd quarter. Aberdeen Group plc now owns 556,733 shares of the company’s stock worth $7,043,000 after buying an additional 72,770 shares during the period. Vanguard Group Inc. grew its holdings in shares of Dyne Therapeutics by 27.6% during the 3rd quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock worth $123,469,000 after purchasing an additional 2,109,257 shares in the last quarter. Saturn V Capital Management LP bought a new position in Dyne Therapeutics in the 2nd quarter valued at about $13,856,000. Arcadia Investment Management Corp MI raised its position in Dyne Therapeutics by 23.1% during the second quarter. Arcadia Investment Management Corp MI now owns 55,215 shares of the company’s stock valued at $526,000 after purchasing an additional 10,350 shares in the last quarter. Finally, Squarepoint Ops LLC raised its holdings in shares of Dyne Therapeutics by 334.3% during the 2nd quarter. Squarepoint Ops LLC now owns 181,740 shares of the company’s stock worth $1,730,000 after buying an additional 139,896 shares in the last quarter. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics News Roundup

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: New 24‑month DELIVER results showed improvements in lung function (FVC% predicted) and cardiac measures (circumferential strain and LVEF) versus expected DMD natural history, reinforcing efficacy signals for z‑rostudirsen (DYNE‑251) and supporting the program’s regulatory path. Read More.
• Positive Sentiment: Dyne launched the Phase 3 HARMONIA trial of z‑basivarsen (DYNE‑101) in myotonic dystrophy type 1; the trial is FDA‑aligned and intended as a confirmatory program for traditional approval, which is a major clinical/regulatory inflection point if enrollment and endpoints proceed. Read More.
• Positive Sentiment: Analyst support is bullish: Chardan reaffirmed a “buy” with a $38 price target (material upside vs. current levels), and multiple firms carry buy/outperform ratings and high median targets (~$38.5), which can underpin momentum and investor interest. Read More.
• Positive Sentiment: Independent writeups highlight Dyne’s ~$1.1B cash runway into mid‑2028 and argue DELIVER/HARMONIA data strengthen the bull case — supporting funding for ongoing registrational programs. Read More.
• Neutral Sentiment: Management presented at TD Cowen (prepared remarks/transcript available), increasing visibility to investors and clinicians but providing no new clinical readouts beyond the recent releases. Read More.
• Neutral Sentiment: Media coverage (MarketWatch, QuiverQuant, local outlets) has amplified the DELIVER/ HARMONIA headlines, helping trading volume and retail/institutional attention; press coverage is supportive but mostly derivative of company releases. Read More.
• Negative Sentiment: Important caveat in the DELIVER release: most patients at the 24‑month timepoint spent substantial time on doses (0.7–2.8 mg/kg) well below the registrational 20 mg/kg Q4W, so observed long‑term efficacy may not reflect outcomes at the intended commercial dose — a clinical/regulatory risk. Read More.
• Negative Sentiment: Insider and hedge‑fund activity is mixed/negative: recent Quiver data show multiple insider sales (no purchases) and large institutional reshuffling (e.g., RA Capital materially reduced exposure in prior quarters), which can signal profit‑taking or differing convictions among sophisticated holders. Read More.
• Negative Sentiment: Reported short‑interest data in the feed are inconsistent/uncertain (zero shares / NaN change), so short‑squeeze dynamics aren’t clearly supported by the data; lack of transparent short interest may add volatility but is not a confirmed driver.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.